Blood Science, an authoritative journal in the fields of hematology and oncology, has been at the forefront of advancing knowledge in blood-related disorders. Dedicated to publishing pioneering research, the journal provides a platform for understanding the complexities of blood ecosystems, from cellular mechanisms to clinical implications. By fostering collaboration and disseminating groundbreaking studies, Blood Science has shaped the way researchers and clinicians approach hematological health and disease.

In this special issue on the blood ecosystem, Blood Science features the work of ,Professor Haojian Zhang from the Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Wuhan University and Professor Fuling Zhou from the Zhongnan Hospital, Wuhan University highlighting the critical role of epigenetic modifications in hematopoiesis and acute myeloid leukemia (AML). Their comprehensive analysis elucidates how epigenetic disruptions serve as a driving force behind leukemia development and offers insights into novel therapeutic opportunities.

Epigenetic Regulation in Hematopoiesis and Leukemia

Hematopoietic stem cells (HSCs) are fundamental to maintaining blood and immune cell production, balancing self-renewal and differentiation. This balance is governed by intricate epigenetic mechanisms, such as DNA methylation and RNA modifications. When disrupted, these processes destabilize normal hematopoiesis and enable leukemia stem cells (LSCs) to propagate, driving AML pathogenesis.

The Role of DNA Methylation in Hematopoiesis and AML

DNA methylation, a vital regulatory process, is mediated by DNA methyltransferases (DNMTs). DNMT1 sustains existing methylation patterns, while DNMT3A and DNMT3B establish new ones, ensuring the proper function of HSCs. Mutations in DNMT3A, frequently observed in AML, lead to aberrant methylation, impaired differentiation, and unchecked proliferation of myeloid progenitors. These mutations disrupt DNMT3A’s ability to form functional complexes, compounding the damage.

TET family enzymes, particularly TET2, are essential for reversing DNA methylation and maintaining balance in gene expression. Mutations in TET2, commonly found in AML, hinder this demethylation process, promoting abnormal chromatin states and leukemogenesis. Together, DNMT3A and TET2 mutations create a synergistic disruption that accelerates AML progression.

The interplay between metabolism and epigenetics is further exemplified by isocitrate dehydrogenase (IDH) mutations. These mutations result in the production of the oncometabolite 2-hydroxyglutarate (2HG), which inhibits TET enzymes, leading to global DNA hypermethylation. This blockade disrupts differentiation and promotes LSC expansion, emphasizing the multifaceted role of epigenetic dysregulation in AML.

RNA Modifications and AML Pathogenesis

RNA modifications, particularly N6-methyladenosine (m6A), are emerging as critical regulators of hematopoiesis. Controlled by “writers,” “erasers,” and “readers,” m6A modulates RNA stability, translation, and splicing. It plays a crucial role in hematopoiesis by regulating key genes like MYC, ensuring proper HSC self-renewal and differentiation.

In AML, aberrant m6A modifications rewire cellular processes to favor LSC survival and proliferation. These modifications enhance metabolic pathways, such as fatty acid and glutamine metabolism, supporting the energy demands of leukemic cells. Additionally, m6A cooperates with chromatin remodeling mechanisms to amplify oncogenic signals, demonstrating its integral role in AML progression.

Therapeutic Implications of Epigenetic Modifications

The understanding of epigenetic modifications has opened new therapeutic avenues. DNMT inhibitors, such as azacitidine and decitabine, aim to restore normal methylation patterns and are already in clinical use. TET agonists are under development to counteract TET2 mutations, with the goal of restoring DNA demethylation and normal hematopoiesis.

Targeting RNA modifications, particularly m6A, is another promising approach. Modulating m6A pathways could disrupt LSC-specific epigenetic programs, impairing leukemic cell survival while sparing normal HSCs. Similarly, IDH inhibitors are being explored to neutralize the effects of 2HG, reactivating TET proteins and normalizing DNA methylation patterns.

Despite these advances, challenges remain. Developing specific inhibitors that selectively target abnormal epigenetic processes without affecting normal functions is a key focus. Additionally, the heterogeneity of AML mutations necessitates personalized therapeutic approaches to ensure efficacy across diverse patient populations.

Conclusion

Epigenetic modifications serve as master regulators of hematopoiesis and key drivers of leukemogenesis in AML. The interplay between DNA and RNA modifications not only underpins the development of leukemia but also offers unique opportunities for targeted therapeutic interventions. As highlighted in this study published by Blood Science, a deeper understanding of these mechanisms promises to revolutionize the treatment landscape for AML and other hematological malignancies, providing new hope for patients worldwide.

Click the link to view the original article：

https://journals.lww.com/bls/fulltext/2024/10000/epigenetic_modifications_in_hematopoietic.8.aspx